天康生物(002100) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥4,180,253,944.24, representing a 10.68% increase compared to ¥3,776,851,559.41 in the same period last year[5] - Net profit attributable to shareholders increased by 174.02% to ¥148,142,983.18 from ¥54,063,760.85 year-on-year[5] - Basic and diluted earnings per share rose by 175.00% to ¥0.11 from ¥0.04 in the same quarter last year[5] - Net profit for the current period was ¥171,441,542.03, a significant increase of 184.36% compared to ¥60,176,209.17 in the previous period[18] - Earnings per share (EPS) for the current period was ¥0.11, compared to ¥0.04 in the previous period, reflecting a 175% increase[19] Cash Flow - The net cash flow from operating activities improved significantly to ¥124,044,426.30, a 137.16% increase from a negative cash flow of ¥333,850,669.38 in the previous year[5] - Cash flow from operating activities generated a net cash inflow of ¥124,044,426.30, a recovery from a net outflow of ¥333,850,669.38 in the previous period[20] - Net cash flow from investing activities was -$72,139,359.20, compared to -$187,478,990.29 in the previous period, indicating a decrease in cash outflow[21] - Cash inflow from financing activities totaled $1,180,253,285.90, slightly down from $1,251,700,000.00 in the prior period[21] - The net cash flow from financing activities was $72,786,775.88, down from $397,019,291.42 in the previous period[21] - The net increase in cash and cash equivalents was $124,691,842.98, compared to a decrease of $124,310,368.25 in the prior period[21] - The ending balance of cash and cash equivalents was $3,078,254,392.88, up from $2,548,274,731.17 in the previous period[21] Assets and Liabilities - Total assets at the end of Q1 2025 were ¥17,798,535,319.33, up 1.34% from ¥17,562,512,271.12 at the end of the previous year[5] - Total current assets increased to ¥10,244,239,958.97 from ¥9,847,752,197.03, reflecting a growth of approximately 4.02%[14] - Total non-current assets decreased to ¥7,554,295,360.36 from ¥7,714,760,074.09, a decline of approximately 2.08%[15] - Total liabilities increased to ¥9,148,712,017.42 from ¥9,042,959,631.29, reflecting a growth of about 1.17%[15] - Total assets increased to ¥17,798,535,319.33 from ¥17,562,512,271.12, indicating a growth of about 1.35%[15] Income and Expenses - Total operating costs increased to ¥4,012,088,136.80, up 9.06% from ¥3,678,286,988.75 in the previous period[17] - The company reported a significant increase in other income to ¥17,449,920.54, compared to ¥10,963,408.01 in the previous period, indicating improved operational efficiency[17] - The company reported a decrease in research and development expenses to ¥50,150,345.89, down from ¥66,463,953.07 in the previous period, indicating a focus on cost management[17] Other Financial Metrics - The weighted average return on equity improved to 2.10%, up from 0.84% in the previous year[5] - The company experienced a 7820.55% increase in non-operating income, reaching ¥25,508,794.10, driven by contract changes[9] - The company’s financial assets increased by 180.40% to ¥15,488,965.94, mainly due to the addition of structured deposits[9] - The company reported a significant increase in contract liabilities, which rose by 34.12% to ¥892,793,544.26, attributed to an increase in customer prepayments[9] Corporate Governance - The company’s first quarter report was not audited[22] - The new accounting standards will be implemented starting in 2025[22] - The company’s board of directors meeting was held on April 30, 2025[23]